CervoMed Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $4.0M | $9.7M | $7.1M | $0 | — |
| Research and development | $21.8M | $18.8M | $8.4M | $1.3M | $8.5M |
| Operating expenses | $32.3M | $28.0M | $15.0M | $3.5M | — |
| Operating income | -$28.3M | -$18.2M | -$7.8M | -$3.5M | -$24.7M |
| Interest expense | — | — | $0 | $587 | — |
| Pretax income | — | — | — | -$15.6M | -$24.5M |
| Income tax expense | $0 | — | — | $0 | -$443,893 |
| Net income | -$27.0M | -$16.3M | -$2.2M | -$5.8M | -$24.1M |
| Balance Sheet | |||||
| Cash and equivalents | $8.2M | $9.0M | $7.8M | $4.1M | $37.3M |
| Current assets | $22.9M | $43.1M | $10.0M | $4.2M | $37.8M |
| Total assets | $22.9M | $43.1M | $10.0M | $4.2M | $37.8M |
| Current liabilities | $4.7M | $3.9M | — | — | $2.9M |
| Total liabilities | $4.7M | $3.9M | $2.6M | $13.2M | $2.9M |
| Stockholders' equity | $18.2M | $39.2M | $7.4M | -$33.3M | $34.9M |
| Cash Flow Statement | |||||
| Cash from operations | -$23.4M | -$16.5M | -$7.4M | -$2.6M | -$14.5M |
| Depreciation and amortization | — | — | — | $0 | $93,416 |
| Stock-based compensation | $1.4M | $1.4M | $407,632 | $333,835 | $897,260 |
| Share repurchases | — | — | $0 | — | — |
| Impairments | — | — | — | $0 | $8.6M |
Shares outstanding 9.3M · Free float 100.0%
Annual filing data through FY ended December 31, 2025; float as of July 12, 2026.